PUBLIC CONTRACT · 2022
PC2022030414 - CD25 pe bd biosciences; CD5 pe-CY7; anti-human CD11B apc-cy
- Contract value
- €2,304.45
- Signed on
- 12 April 2022
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9226390PUBLISHED SUBJECT
PC2022030414 - CD25 PE BD BIOSCIENCES; CD5 PE-CY7; ANTI-HUMAN CD11B APC-CY
Parties involved
- Place of performance
- Portugal, Porto, Porto
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ENZIfarma ? Diagnostica e Farmacêutica, S.A. · Tax ID 503636975
Values and timeline
- Contract price
- €2,304.45
- Procedure base price
- €2,304.45
- Total effective price
- Not reported on Portal BASE
- Publication date
- 9 May 2022
- Award date
- 28 March 2022
- Signing date
- 12 April 2022
- Performance period
- 20 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33000000-0 - Equipamento médico, medicamentos e produtos para cuidados pessoais
- Legal basis
- Artigo 24.º, n.º 1, alínea c) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5890440
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.